OQRO
← Public records

Healthcare

Clinical trials sponsored by listed companies

Studies on ClinicalTrials.gov whose lead sponsor is a listed company, most recently updated first, with the phase and status.

How to read it. A registered study is not an approved treatment, and a completed study is not a positive result. Last update: the day the sponsor last updated the entry.

Guide: Trial phases and ClinicalTrials.gov statuses

As of Oct 20, 2026, OQRO holds 2,492 clinical trials from ClinicalTrials.gov; the latest is dated Oct 9, 2026. The 100 shown below are the most recent. Over the last 12 months, Astrazeneca (AZN) has the most on file: 277.

Clinical trials per month, last 24 months · 2,471 in total

Nov 24: 4Nov 24Dec 24: 3Jan 25: 10Feb 25: 7Feb 25Mar 25: 7Apr 25: 5May 25: 7May 25Jun 25: 13Jul 25: 14Aug 25: 25Aug 25Sep 25: 20Oct 25: 25Nov 25: 21Nov 25Dec 25: 48Jan 26: 51Feb 26: 70Feb 26Mar 26: 72Apr 26: 101May 26: 121May 26Jun 26: 127Jul 26: 260Aug 26: 334Aug 26Sep 26: 678678Oct 26: 448448

Most clinical trials, last 12 months

100 of the 100 most recent shown (2,492 on file)

  1. Disc Medicine IRONLast update Oct 9, 2026

    HELIOS: Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Efficacy of DISC-1459 (Bitopertin) in Participants With EPP or XLP

    NCT05883748, Phase 2/3, enrolling by invitation, primary completion 2028-06

    View original source

  2. Immuneering IMRXLast update Oct 9, 2026

    Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma

    NCT07562152, Phase 3, recruiting, primary completion 2028-06

    View original source

  3. Novo Nordisk NVOLast update Oct 9, 2026

    A Research Study to Look at Long-term Treatment With a Medicine Called NNC6019-0001 for People Who Have Heart Failure Due to Transthyretin Amyloidosis

    NCT06260709, Phase 2, active not recruiting, primary completion 2028-02-29

    View original source

  4. Contineum Therapeutics CTNMLast update Oct 9, 2026

    Study to Evaluate the Efficacy, Safety, and Tolerability of PIPE 791 in Subjects With Idiopathic Pulmonary Fibrosis

    NCT07284459, Phase 2, recruiting, primary completion 2028-05

    View original source

  5. AbbVie ABBVLast update Oct 9, 2026

    A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Particip…

    NCT07059845, Phase 2, recruiting, primary completion 2029-01

    View original source

  6. Mediwound MDWDLast update Oct 9, 2026

    A Double Blind Study Performed to Evaluate the Efficacy and the Safety of EscharEx in Debridement of VLU (VALUE)

    NCT06568627, Phase 3, recruiting, primary completion 2026-12

    View original source

  7. Merck MRKLast update Oct 9, 2026

    A Clinical Trial of Calderasib (MK-1084) and Durvalumab in People With Non-Small Cell Lung Cancer (MK-1084-015/KANDLELIT-015)

    NCT07554339, Phase 3, recruiting, primary completion 2032-12-15

    View original source

  8. Merck MRKLast update Oct 9, 2026

    A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-240…

    NCT06863272, Phase 2, recruiting, primary completion 2031-10-01

    View original source

  9. Trevi Therapeutics TRVILast update Oct 9, 2026

    Idiopathic Pulmonary Fibrosis (IPF)-Related Chronic Cough Reduction With Nalbuphine (NAL) Extended-Release (ER) Tablets

    NCT07868419, Phase 3, recruiting, primary completion 2027-08

    View original source

  10. Astrazeneca AZNLast update Oct 9, 2026

    AZD0486 1L Therapy for Elderly or Unfit Participants With LBCL

    NCT07215585, Phase 3, recruiting, primary completion 2030-06-10

    View original source

  11. Astrazeneca AZNLast update Oct 9, 2026

    A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00007)

    NCT06878261, Phase 3, recruiting, primary completion 2029-03-13

    View original source

  12. Biogen BIIBLast update Oct 9, 2026

    A Study to Learn More About the Long-Term Safety and Effects of Felzartamab Infusions in Adults With Kidney Transplants Who Have Antibody-Mediated Rejection (A…

    NCT07444489, Phase 3, enrolling by invitation, primary completion 2031-12-31

    View original source

  13. Incyte INCYLast update Oct 9, 2026

    A Study to Evaluate Axatilimab Versus Best Available Therapy in Pediatric Participants With Chronic Graft-Versus-Host Disease After at Least 2 Prior Lines of S…

    NCT07124078, Phase 2, recruiting, primary completion 2029-01-31

    View original source

  14. Astrazeneca AZNLast update Oct 9, 2026

    A Study to Investigate Efficacy and Safety of AZD1163 in Participants With Rheumatoid Arthritis

    NCT07276581, Phase 2, recruiting, primary completion 2027-11-12

    View original source

  15. Larimar Therapeutics LRMRLast update Oct 9, 2026

    A Study to Evaluate the Efficacy and Safety of Subcutaneous Nomlabofusp in Subjects With Friedreich's Ataxia

    NCT07778836, Phase 3, recruiting, primary completion 2029-07

    View original source

  16. Moonlake Immunotherapeutics MLTXLast update Oct 9, 2026

    Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis Naive to Biologic Disease-Modifying Antirheumatic Drug

    NCT06641076, Phase 3, active not recruiting, primary completion 2026-05-28

    View original source

  17. Merck MRKLast update Oct 9, 2026

    A Clinical Trial of MK-8748 Compared to Aflibercept in Participants With Diabetic Macular Edema (MK-8748-005)

    NCT07705607, Phase 3, recruiting, primary completion 2028-11-30

    View original source

  18. Merck MRKLast update Oct 9, 2026

    A Clinical Trial of MK-2010 With Sacituzumab Tirumotecan (Sac-TMT) in Participants With Solid Tumors (MK-2010)

    NCT07785609, Phase 2, recruiting, primary completion 2031-09-30

    View original source

  19. Regeneron Pharmaceuticals REGNLast update Oct 9, 2026

    Safety in Adult Participants With Atrial Fibrillation Who Are Treated With Anticoagulation

    NCT07175428, Phase 2, recruiting, primary completion 2027-02-09

    View original source

  20. Sanofi SNYLast update Oct 9, 2026

    A Study to Investigate the Efficacy and Safety of Brivekimig in Adult Participants With Ulcerative Colitis

    NCT06975722, Phase 2, active not recruiting, primary completion 2026-12-17

    View original source

  21. Vertex Pharmaceuticals VRTXLast update Oct 9, 2026

    A Study Evaluating the Long-term Safety and Efficacy of VX-121 Combination Therapy

    NCT05444257, Phase 3, active not recruiting, primary completion 2026-10-30

    View original source

  22. AbbVie ABBVLast update Oct 9, 2026

    A Study to Assess Adverse Events and Effectiveness of Gel Stent (XEN63) Implantation Using Ab Interno and Ab Externo Approaches in Adult Participants With Glau…

    NCT06822738, Phase 3, recruiting, primary completion 2028-11

    View original source

  23. Vertex Pharmaceuticals VRTXLast update Oct 9, 2026

    Study to Evaluate Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) Long-term Safety and Efficacy in Subjects Without F508del

    NCT05331183, Phase 3, active not recruiting, primary completion 2027-04-06

    View original source

  24. Viking Therapeutics VKTXLast update Oct 9, 2026

    Oral VK2735 for Weight Management in Adults With Type 2 Diabetes Mellitus Phase 3 (SUNRISE 2)

    NCT07868939, Phase 3, not yet recruiting, primary completion 2028-10

    View original source

  25. Alterity Therapeutics ATHELast update Oct 9, 2026

    Open-Label Access to ATH434 for Patients Who Completed Study ATH434-201 in France

    NCT07729852, Phase 2, enrolling by invitation, primary completion 2029-07

    View original source

  26. Incyte INCYLast update Oct 9, 2026

    Pharmacokinetics, Safety, and Efficacy of Povorcitinib in Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa

    NCT07213973, Phase 2, recruiting, primary completion 2028-03-25

    View original source

  27. Incyte INCYLast update Oct 9, 2026

    A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Children (6 to < 12 Years Old) With Nonsegmental Vitiligo

    NCT06804811, Phase 3, recruiting, primary completion 2027-04-30

    View original source

  28. Incyte INCYLast update Oct 9, 2026

    A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastati…

    NCT07284849, Phase 3, recruiting, primary completion 2028-12-29

    View original source

  29. Merck MRKLast update Oct 9, 2026

    A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003)

    NCT07227597, Phase 2, recruiting, primary completion 2030-11-29

    View original source

  30. Biontech BNTXLast update Oct 9, 2026

    A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investig…

    NCT07070232, Phase 2, recruiting, primary completion 2028-03

    View original source

  31. Eli Lilly LLYLast update Oct 9, 2026

    A Study of LY4005130 in Adult Participants With Severe Alopecia Areata (Hair Loss)

    NCT07533006, Phase 2, recruiting, primary completion 2027-06

    View original source

  32. Eli Lilly LLYLast update Oct 9, 2026

    A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 Diabetes

    NCT07215559, Phase 2, active not recruiting, primary completion 2027-03

    View original source

  33. Larimar Therapeutics LRMRLast update Oct 9, 2026

    An Open-Label Study of CTI-1601 in Subjects With Friedreich's Ataxia

    NCT06447025, Phase 2, recruiting, primary completion 2027-01

    View original source

  34. Moonlake Immunotherapeutics MLTXLast update Oct 9, 2026

    Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis and Anti-TNFα Inadequate Response

    NCT06641089, Phase 3, active not recruiting, primary completion 2027-01-04

    View original source

  35. Incyte INCYLast update Oct 9, 2026

    Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib

    NCT06855498, Phase 3, recruiting, primary completion 2028-02-28

    View original source

  36. Merck MRKLast update Oct 9, 2026

    A Clinical Trial of Tulisokibart (MK-7240) in Participants With Pulmonary Sarcoidosis (MK-7240-016)

    NCT07867938, Phase 2, not yet recruiting, primary completion 2029-10-05

    View original source

  37. Eli Lilly LLYLast update Oct 9, 2026

    A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide

    NCT06897475, Phase 2, recruiting, primary completion 2027-05

    View original source

  38. Merck MRKLast update Oct 9, 2026

    A Clinical Trial of MK-8748 Compared to Aflibercept in Participants With Diabetic Macular Edema (MK-8748-004)

    NCT07705555, Phase 3, recruiting, primary completion 2028-10-31

    View original source

  39. Pfizer PFELast update Oct 9, 2026

    Symbiotic-Lung-14: A Study to Learn About the Study Medicine Called PF08634404 in Combination With Chemotherapy in Adult Participants With Transformed Small Ce…

    NCT07476287, Phase 2, recruiting, primary completion 2028-03-24

    View original source

  40. Pfizer PFELast update Oct 9, 2026

    A Study to Learn About the Study Medicine Called Tilrekimig ( PF-07275315) in People With Severe Asthma

    NCT07869043, Phase 3, recruiting, primary completion 2029-06-07

    View original source

  41. Rhythm Pharmaceuticals RYTMLast update Oct 9, 2026

    A Study of RM-718 in Healthy Subjects and Patients With MC4R Pathway Impairment

    NCT06239116, Phase 2, active not recruiting, primary completion 2027-05-07

    View original source

  42. Syndax Pharmaceuticals SNDXLast update Oct 9, 2026

    A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation

    NCT04065399, Phase 2, recruiting, primary completion 2027-12-15

    View original source

  43. Iovance Biotherapeutics IOVALast update Oct 9, 2026

    A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Soft Tissue Sarcoma

    NCT07741877, Phase 2, recruiting, primary completion 2033-09-01

    View original source

  44. Vertex Pharmaceuticals VRTXLast update Oct 9, 2026

    A Safety, Tolerability, and Efficacy Study of VX-264 in Participants With Type 1 Diabetes

    NCT05791201, Phase 2, active not recruiting, primary completion 2027-03-12

    View original source

  45. Verastem VSTMLast update Oct 9, 2026

    A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Colorectal Cancer

    NCT07659795, Phase 2, recruiting, primary completion 2027-06

    View original source

  46. Verastem VSTMLast update Oct 9, 2026

    A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer

    NCT07644559, Phase 2, recruiting, primary completion 2027-06

    View original source

  47. Eli Lilly LLYLast update Oct 9, 2026

    A Study of Pirtobrutinib in Participants With Immune Thrombocytopenia

    NCT06721013, Phase 2, recruiting, primary completion 2028-02

    View original source

  48. Biogen BIIBLast update Oct 9, 2026

    A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus

    NCT05531565, Phase 2/3, active not recruiting, primary completion 2026-10-20

    View original source

  49. Vertex Pharmaceuticals VRTXLast update Oct 9, 2026

    Evaluation of the Long-term Safety and Effectiveness of Suzetrigine (SUZ) in Participants With Painful Diabetic Peripheral Neuropathy (DPN)

    NCT06696443, Phase 3, active not recruiting, primary completion 2027-01-25

    View original source

  50. Viking Therapeutics VKTXLast update Oct 9, 2026

    Oral VK2735 for Weight Management Phase 3 (SUNRISE 1)

    NCT07868835, Phase 3, not yet recruiting, primary completion 2028-07

    View original source

  51. Astrazeneca AZNLast update Oct 9, 2026

    Evaluating the Efficacy and Safety of PT027 Compared With PT007 Administered As Needed in Participants 12 to < 18 Years of Age With Asthma

    NCT06307665, Phase 3, recruiting, primary completion 2027-10-13

    View original source

  52. Astrazeneca AZNLast update Oct 9, 2026

    Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations

    NCT05687266, Phase 3, active not recruiting, primary completion 2027-11-01

    View original source

  53. Astrazeneca AZNLast update Oct 9, 2026

    First-in-Human Study to Evaluate AZD8359 STEAP2 TCE in Participants With Prostate Cancer

    NCT07529717, Phase 2, recruiting, primary completion 2027-11-17

    View original source

  54. Celcuity CELCLast update Oct 9, 2026

    Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)

    NCT06757634, Phase 3, recruiting, primary completion 2029-03-31

    View original source

  55. Pfizer PFELast update Oct 9, 2026

    A Study to Learn About the Safety and Immune Responses of RSVpreF in Older Adults

    NCT07819097, Phase 3, recruiting, primary completion 2027-05-16

    View original source

  56. Corcept Therapeutics CORTLast update Oct 9, 2026

    Extension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patients With Cushing Syndrome

    NCT03604198, Phase 2, active not recruiting, primary completion 2026-12

    View original source

  57. AbbVie ABBVLast update Oct 9, 2026

    A Study to Assess Adverse Events and Change in Disease Activity in Adult Participants Receiving Intravenously Infused Telisotuzumab Adizutecan Alone or With St…

    NCT07023289, Phase 2, recruiting, primary completion 2029-11

    View original source

  58. Bristol Myers Squibb BMYLast update Oct 9, 2026

    Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIG…

    On the record as Bristol-Myers Squibb · NCT07100080, Phase 2/3, recruiting, primary completion 2028-12-15

    View original source

  59. 4d Molecular Therapeutics FDMTLast update Oct 9, 2026

    Phase 3 Study of Intravitreal 4D-150 in Adults With Diabetic Macular Edema (DME) (4D-150-C005)

    NCT07867080, Phase 3, recruiting, primary completion 2029-01

    View original source

  60. Incyte INCYLast update Oct 9, 2026

    A Study to Evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease

    NCT06585774, Phase 3, recruiting, primary completion 2027-09-28

    View original source

  61. AbbVie ABBVLast update Oct 9, 2026

    A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years

    NCT06810505, Phase 3, recruiting, primary completion 2031-03

    View original source

  62. Astrazeneca AZNLast update Oct 9, 2026

    A Phase I/II Study on Safety AND Immunogenicity of AZD4117 and AZD5315 Vaccines (PANDA)

    NCT07128615, Phase 2, active not recruiting, primary completion 2026-01-28

    View original source

  63. Atossa Therapeutics ATOSLast update Oct 9, 2026

    (Z)-Endoxifen in Girls With MAS-Associated Peripheral Precocious Puberty

    NCT07869732, Phase 2, not yet recruiting, primary completion 2028-06

    View original source

  64. Incyte INCYLast update Oct 9, 2026

    Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression

    NCT07214779, Phase 3, recruiting, primary completion 2028-11-15

    View original source

  65. Cabaletta Bio CABALast update Oct 9, 2026

    RESET-MG: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Generalized Myasthenia Gravis

    NCT06359041, Phase 2, recruiting, primary completion 2029-09

    View original source

  66. Astrazeneca AZNLast update Oct 9, 2026

    A Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Participants With Metastatic Non-small Cell Lung Cancer.

    NCT05984277, Phase 3, active not recruiting, primary completion 2026-08-17

    View original source

  67. Incyte INCYLast update Oct 9, 2026

    Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors

    NCT03934372, Phase 2, recruiting, primary completion 2028-02-01

    View original source

  68. Merck MRKLast update Oct 9, 2026

    A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small…

    NCT07513376, Phase 3, recruiting, primary completion 2034-08-22

    View original source

  69. AbbVie ABBVLast update Oct 8, 2026

    Surabgene Lomparvovec Administered in the Suprachoroidal Space in Adult Participants With Diabetic Retinopathy Without Center-Involved Diabetic Macular Edema

    NCT07592273, Phase 2/3, recruiting, primary completion 2028-06

    View original source

  70. Astrazeneca AZNLast update Oct 8, 2026

    A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors

    NCT07115043, Phase 2, recruiting, primary completion 2029-10-02

    View original source

  71. Alnylam Pharmaceuticals ALNYLast update Oct 8, 2026

    A Study to Evaluate ALN-AGT01 RVR in Adult Patients With Mild to Moderate Hypertension Pretreated With Zilebesiran

    NCT07553442, Phase 2, recruiting, primary completion 2028-04-01

    View original source

  72. AbbVie ABBVLast update Oct 8, 2026

    A Study to Learn More About How Risankizumab Works in Young Participants With Ulcerative Colitis

    NCT07071519, Phase 3, recruiting, primary completion 2034-07

    View original source

  73. Amgen AMGNLast update Oct 8, 2026

    Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Ov…

    NCT07575399, Phase 3, recruiting, primary completion 2028-01-03

    View original source

  74. Eli Lilly LLYLast update Oct 8, 2026

    A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight

    NCT07589608, Phase 2, recruiting, primary completion 2027-09

    View original source

  75. Astrazeneca AZNLast update Oct 8, 2026

    AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)

    NCT05850234, Phase 2, recruiting, primary completion 2027-10-01

    View original source

  76. Merck MRKLast update Oct 8, 2026

    A Clinical Trial of MK-1045 and Rituximab in People With Follicular Lymphoma (MK-1045-007)

    NCT07634471, Phase 2/3, recruiting, primary completion 2032-07-23

    View original source

  77. Eli Lilly LLYLast update Oct 8, 2026

    A Study to Evaluate LY3537021 for the Treatment of Nausea and Vomiting Caused by Chemotherapy in Adults With Cancer

    NCT07169851, Phase 2, recruiting, primary completion 2026-12

    View original source

  78. Eli Lilly LLYLast update Oct 8, 2026

    A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes Who Observe Ramadan Fasting

    NCT07613307, Phase 3, recruiting, primary completion 2027-05

    View original source

  79. Eli Lilly LLYLast update Oct 8, 2026

    A Study of Brenipatide (LY3537031) in Participants With Irritable Bowel Syndrome-Constipation (IBS-C)

    NCT07545772, Phase 2, recruiting, primary completion 2027-07

    View original source

  80. Eli Lilly LLYLast update Oct 8, 2026

    A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)

    NCT07165028, Phase 3, recruiting, primary completion 2030-08

    View original source

  81. Aura Biosciences AURALast update Oct 8, 2026

    Suprachoroidal Administration in Subjects With Metastases to the Choroid

    NCT06643884, Phase 2, recruiting, primary completion 2026-11-30

    View original source

  82. Eli Lilly LLYLast update Oct 8, 2026

    A Study of LY4005130 in Adult Participants With Non-Segmental Vitiligo

    NCT07533019, Phase 2, recruiting, primary completion 2027-05

    View original source

  83. Astrazeneca AZNLast update Oct 8, 2026

    A Study of AZD0292 in Chinese Participants With Bronchiectasis and Chronic Pseudomonas Aeruginosa Colonization

    NCT07774403, Phase 2, recruiting, primary completion 2028-01-18

    View original source

  84. Eli Lilly LLYLast update Oct 8, 2026

    LY4268989 (MORF-057) Co-Administered With Mirikizumab in Adults With Moderately to Severely Active Ulcerative Colitis:

    NCT07186101, Phase 2, recruiting, primary completion 2027-05

    View original source

  85. Eli Lilly LLYLast update Oct 8, 2026

    A Study of Brenipatide (LY3537031) in Adult Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD)

    NCT07759245, Phase 2, recruiting, primary completion 2028-05

    View original source

  86. Eli Lilly LLYLast update Oct 8, 2026

    A Study of Clazakizumab (LY5724886) in Adults With Elevated hsCRP and at Increased Risk for Cardiovascular Event

    NCT07783802, Phase 2, recruiting, primary completion 2027-05

    View original source

  87. Eli Lilly LLYLast update Oct 8, 2026

    A Study of Baricitinib (LY3009104) to Preserve Beta Cell Function in Children and Adults Newly Diagnosed With Type 1 Diabetes (BARICADE-PRESERVE)

    NCT07222332, Phase 3, recruiting, primary completion 2028-07

    View original source

  88. Eli Lilly LLYLast update Oct 8, 2026

    A Study of Brenipatide in Participants With Alcohol Use Disorder

    NCT07219953, Phase 3, recruiting, primary completion 2028-04

    View original source

  89. Eli Lilly LLYLast update Oct 8, 2026

    A Master Protocol (IIBD): A Study of Multiple Drugs in Adults With Ulcerative Colitis or Crohn's Disease

    NCT07483073, Phase 2, recruiting, primary completion 2027-06

    View original source

  90. Maze Therapeutics MAZELast update Oct 8, 2026

    A Study of MZE782 in Adults With PKU

    NCT07694440, Phase 2, recruiting, primary completion 2027-12

    View original source

  91. Eli Lilly LLYLast update Oct 8, 2026

    A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outc…

    NCT07241390, Phase 3, recruiting, primary completion 2031-08

    View original source

  92. Eli Lilly LLYLast update Oct 8, 2026

    Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight

    NCT07353931, Phase 3, recruiting, primary completion 2028-03

    View original source

  93. Eli Lilly LLYLast update Oct 8, 2026

    A Study of Baricitinib (LY3009104) for the Delay of Stage 3 Type 1 Diabetes in At-Risk Children and Adults

    NCT07222137, Phase 3, recruiting, primary completion 2031-07

    View original source

  94. Korro Bio KRROLast update Oct 8, 2026

    Phase 1/2 Study of KRRO-121 in Healthy Volunteers and Patients With UCD

    NCT07773246, Phase 2, recruiting, primary completion 2027-08

    View original source

  95. Eli Lilly LLYLast update Oct 8, 2026

    A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)

    NCT07174336, Phase 3, recruiting, primary completion 2029-05

    View original source

  96. Climb Bio CLYMLast update Oct 8, 2026

    A Phase 2 Study of Budoprutug in Subjects With Primary Membranous Nephropathy

    NCT07096843, Phase 2, recruiting, primary completion 2027-10

    View original source

  97. Amgen AMGNLast update Oct 8, 2026

    Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesi…

    NCT07037433, Phase 3, recruiting, primary completion 2028-06-30

    View original source

  98. Eli Lilly LLYLast update Oct 8, 2026

    A Study of Vepugratinib (LY3866288) in Adults With Non-Muscle Invasive Bladder Cancer and Upper Tract Urothelial Cancer

    NCT07827612, Phase 2, not yet recruiting, primary completion 2028-07

    View original source

  99. Eli Lilly LLYLast update Oct 8, 2026

    A Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or Overweight

    NCT07369011, Phase 3, recruiting, primary completion 2028-03

    View original source

  100. Eli Lilly LLYLast update Oct 8, 2026

    A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer

    NCT07213804, Phase 3, recruiting, primary completion 2028-11

    View original source